These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 18975341)

  • 1. Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.
    Yao W; Cheng Z; Pham A; Busse C; Zimmermann EA; Ritchie RO; Lane NE
    Arthritis Rheum; 2008 Nov; 58(11):3485-97. PubMed ID: 18975341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization.
    Yao W; Balooch G; Balooch M; Jiang Y; Nalla RK; Kinney J; Wronski TJ; Lane NE
    Bone; 2006 Sep; 39(3):460-9. PubMed ID: 16713415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged treatments with antiresorptive agents and PTH have different effects on bone strength and the degree of mineralization in old estrogen-deficient osteoporotic rats.
    Cheng Z; Yao W; Zimmermann EA; Busse C; Ritchie RO; Lane NE
    J Bone Miner Res; 2009 Feb; 24(2):209-20. PubMed ID: 18847326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids.
    Balooch G; Yao W; Ager JW; Balooch M; Nalla RK; Porter AE; Ritchie RO; Lane NE
    Arthritis Rheum; 2007 Nov; 56(11):3726-37. PubMed ID: 17968931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
    Borah B; Ritman EL; Dufresne TE; Jorgensen SM; Liu S; Sacha J; Phipps RJ; Turner RT
    Bone; 2005 Jul; 37(1):1-9. PubMed ID: 15894527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
    Iwaniec UT; Mosekilde L; Mitova-Caneva NG; Thomsen JS; Wronski TJ
    Endocrinology; 2002 Jul; 143(7):2515-26. PubMed ID: 12072383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
    Ma Y; Jee WS; Chen Y; Gasser J; Ke HZ; Li XJ; Kimmel DB
    J Bone Miner Res; 1995 Nov; 10(11):1726-34. PubMed ID: 8592950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel flavonoid C-glucoside from Ulmus wallichiana preserves bone mineral density, microarchitecture and biomechanical properties in the presence of glucocorticoid by promoting osteoblast survival: a comparative study with human parathyroid hormone.
    Khan MP; Mishra JS; Sharan K; Yadav M; Singh AK; Srivastava A; Kumar S; Bhaduaria S; Maurya R; Sanyal S; Chattopadhyay N
    Phytomedicine; 2013 Nov; 20(14):1256-66. PubMed ID: 23928508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
    Borah B; Dufresne TE; Ritman EL; Jorgensen SM; Liu S; Chmielewski PA; Phipps RJ; Zhou X; Sibonga JD; Turner RT
    Bone; 2006 Aug; 39(2):345-52. PubMed ID: 16571382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risedronate did not block the maximal anabolic effect of PTH in aged rats.
    Yao W; Su M; Zhang Q; Tian X; Setterberg RB; Blanton C; Lundy MW; Phipps R; Jee WS
    Bone; 2007 Nov; 41(5):813-9. PubMed ID: 17716965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittent parathyroid hormone administration counteracts the adverse effects of glucocorticoids on osteoblast and osteocyte viability, bone formation, and strength in mice.
    Weinstein RS; Jilka RL; Almeida M; Roberson PK; Manolagas SC
    Endocrinology; 2010 Jun; 151(6):2641-9. PubMed ID: 20410195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoid attenuates the anabolic effects of parathyroid hormone on fracture repair.
    Doyon AR; Ferries IK; Li J
    Calcif Tissue Int; 2010 Jul; 87(1):68-76. PubMed ID: 20445968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats.
    Ejersted C; Oxlund H; Eriksen EF; Andreassen TT
    Bone; 1998 Jul; 23(1):43-52. PubMed ID: 9662129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined administration of alfacalcidol and risedronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats.
    Iwamoto J; Seki A; Takeda T; Yamada H; Sato Y; Yeh JK
    Chin J Physiol; 2008 Jun; 51(3):121-8. PubMed ID: 18935906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose PTH increases osteoblast activity via decreased Mef2c/Sost in senescent osteopenic mice.
    Saidak Z; Le Henaff C; Azzi S; Marty C; Marie PJ
    J Endocrinol; 2014 Oct; 223(1):25-33. PubMed ID: 25056116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment.
    Oxlund H; Ortoft G; Thomsen JS; Danielsen CC; Ejersted C; Andreassen TT
    Bone; 2006 Aug; 39(2):244-52. PubMed ID: 16503210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
    Borah B; Dufresne TE; Chmielewski PA; Johnson TD; Chines A; Manhart MD
    Bone; 2004 Apr; 34(4):736-46. PubMed ID: 15050906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.
    Otomo H; Sakai A; Ikeda S; Tanaka S; Ito M; Phipps RJ; Nakamura T
    J Bone Miner Metab; 2004; 22(5):404-14. PubMed ID: 15316861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancellous and cortical bone architecture and turnover at the iliac crest of postmenopausal osteoporotic women treated with parathyroid hormone 1-84.
    Recker RR; Bare SP; Smith SY; Varela A; Miller MA; Morris SA; Fox J
    Bone; 2009 Jan; 44(1):113-9. PubMed ID: 18983947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1.
    Bodine PV; Seestaller-Wehr L; Kharode YP; Bex FJ; Komm BS
    J Cell Physiol; 2007 Feb; 210(2):352-7. PubMed ID: 17044082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.